Skip to main content

View Resource

Published

Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. The Lancet Infectious Diseases 2025;:https://doi.org/10.1016/S1473-3099(25)00361-5.
[In patients with COVID-19, sotrovimab was associated with reduced mortality in the primary analysis population who had a high serum SARS-CoV-2 antigen concentration at baseline, but not in the overall population. The emergence of high-level resistance to sotrovimab among subsequent COVID variants restricts its current usefulness, but these results indicate that targeted neutralising antibody therapy could potentially still benefit some patients admitted to hospital who are at high risk of death.]
Freely available online
Age Groups
Adults
Conditions and Lifestyle Factors
Coronavirus Infections
Settings
Hospital Ward
Intensive Care
Staff Groups
Drug Therapy